Latest news with #CleanCap®
Business Wire
5 days ago
- Business
- Business Wire
TriLink BioTechnologies® and Quantoom Biosciences Sign License and Supply Agreement for CleanCap® mRNA Capping Technology
SAN DIEGO--(BUSINESS WIRE)-- TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Under the agreement, Quantoom will have access to TriLink's CleanCap® mRNA capping technology for integration in its Ntensify® (sa)mRNA production platform to help accelerate the RNA production process and make life-saving therapeutics and vaccines more accessible to patients worldwide. "Strengthening global health against infectious diseases requires strong industry partnerships," said Becky Buzzeo, Chief Commercial Officer at Maravai. TriLink's CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when compared to legacy capping methods. Under this agreement, TriLink will supply its patented CleanCap technology for use in Quantoom's (sa)mRNA production platform, allowing customers to benefit from the industry's leading capping technology to develop their unique (sa)mRNA drugs using the Ntensify platform through clinical development phases. "Strengthening global health against infectious diseases requires strong industry partnerships," said Becky Buzzeo, Chief Commercial Officer at Maravai. "We're excited for the Quantoom production platform to incorporate TriLink's CleanCap reagents, a proven mRNA capping technology to deliver essential therapeutics and vaccines to nations with limited resources." Since its debut in 2017, TriLink's CleanCap capping technology has transformed the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines. 'We are committed to making the RNA technology more accessible and scalable, and this partnership with TriLink is a key step toward that goal," said José Castillo, CEO of Quantoom Biosciences. "By integrating CleanCap analogs into our platform, we can further empower researchers and manufacturers to develop life-saving vaccines and therapeutics for communities in need." About TriLink BioTechnologies TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans. For more information about TriLink, visit About Maravai LifeSciences Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. For more information about Maravai LifeSciences, visit About Quantoom Biosciences Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force TM toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode TM for sequence design and optimization, Ntensify ® for RNA production and Ncapsulate ® for RNA-LNP formulation. Launched in 2023, the Ntensify solution enables fully integrated, scalable RNA production by combining processes, equipment, reagent mixes, and disposables and has gained global adoption, being recognized for performance and ease-of-use. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization.
Yahoo
22-05-2025
- Business
- Yahoo
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of 'Maravai LifeSciencesReleases 2024 Sustainability Report'. The corrected title is 'Maravai LifeSciences Releases 2024 Sustainability Report'. Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2024 Sustainability Report, available on the Company's Sustainability webpage ( The new report highlights progress during calendar year 2024 across Maravai's four priority areas – Product Innovation, Our People, Governance, and Sustainable Growth – and underscores the Company's commitment to sustainable value creation. 'By embedding sustainability into every facet of our operations—from employee engagement to GMP scaleup — we foster innovation, strengthen our business resilience, and create long-term value for all stakeholders,' said Trey Martin, Chief Executive Officer. 'Our 2024 achievements position Maravai to remain our customers' first choice as they advance their programs in next-generation therapeutics and diagnostics.' Key highlights from the 2024 report include: Product Innovation Launched 49 new products across portfolio brands, including CleanCap® M6 analog now available at GMP quality Completed state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold Established RNA Innovation Center in collaboration with Johns Hopkins University Added to our GMP manufacturing expertise and have now manufactured over 130 GMP batches for mRNA Our People Achieved 95% participation rate in our annual employee engagement survey, receiving over 2,600 comments Expanded WE (We are Empowered) Employee Resource Group to facilitate advocacy, mentorship, and outreach across the organization Implemented new career framework creating transparent progression paths for all employees Continued our Impact Day program throughout 2024, with employees contributing approximately 800 volunteer hours Governance Appointed healthcare industry veteran R. Andrew Eckert as independent Chairman of the Board Adopted formal, publicly available Human Rights Policy 100% of standing Board Committees chaired by independent members Strengthened intellectual property position with additional CleanCap® patents in China and Canada Sustainable Growth Enhanced greenhouse gas emissions data collection and expanded Scope 3 emissions reporting Leland, North Carolina facility's solar panels generated over 180,000 kWh, offsetting approximately 20% of facility's energy use San Diego EV charging stations helped save over 19,000 gallons of gasoline Advanced planning for lab plastics recycling program and single-use plastic phase-out The 2024 report was prepared in reference to the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB) and Greenhouse Gas Protocol frameworks and maps selected disclosures to relevant U.N. Sustainable Development Goals (SDGs). About Maravai Maravai LifeSciences is an innovative lifesciences company that provides critical products to enable the development of breakthrough therapeutics, vaccines, cell and gene therapies and diagnostics. Through its TriLink BioTechnologies, Glen Research, Alphazyme and Cygnus Technologies brands, Maravai delivers complex nucleic acid chemistries, differentiated mRNA and enzyme solutions, and gold standard biologics safety tests to a global customer base spanning large pharmaceutical companies, emerging biotechs and leading academic institutions. Forward Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements related to future product offerings, facility capabilities, and sustainability initiatives. Forward-looking statements are neither historical facts nor assurances of future performance and are subject to risks and uncertainties that could cause actual results to differ materially. A detailed discussion of these risks is included in Maravai's most recent Annual Report on Form 10K and subsequent filings with the U.S. Securities and Exchange Commission. Maravai undertakes no obligation to update forward-looking statements except as required by law. CONTACT: Contact Information: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@
Yahoo
21-05-2025
- Business
- Yahoo
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of 'Maravai LifeSciencesReleases 2024 Sustainability Report'. The corrected title is 'Maravai LifeSciences Releases 2024 Sustainability Report'. Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2024 Sustainability Report, available on the Company's Sustainability webpage ( The new report highlights progress during calendar year 2024 across Maravai's four priority areas – Product Innovation, Our People, Governance, and Sustainable Growth – and underscores the Company's commitment to sustainable value creation. 'By embedding sustainability into every facet of our operations—from employee engagement to GMP scaleup — we foster innovation, strengthen our business resilience, and create long-term value for all stakeholders,' said Trey Martin, Chief Executive Officer. 'Our 2024 achievements position Maravai to remain our customers' first choice as they advance their programs in next-generation therapeutics and diagnostics.' Key highlights from the 2024 report include: Product Innovation Launched 49 new products across portfolio brands, including CleanCap® M6 analog now available at GMP quality Completed state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold Established RNA Innovation Center in collaboration with Johns Hopkins University Added to our GMP manufacturing expertise and have now manufactured over 130 GMP batches for mRNA Our People Achieved 95% participation rate in our annual employee engagement survey, receiving over 2,600 comments Expanded WE (We are Empowered) Employee Resource Group to facilitate advocacy, mentorship, and outreach across the organization Implemented new career framework creating transparent progression paths for all employees Continued our Impact Day program throughout 2024, with employees contributing approximately 800 volunteer hours Governance Appointed healthcare industry veteran R. Andrew Eckert as independent Chairman of the Board Adopted formal, publicly available Human Rights Policy 100% of standing Board Committees chaired by independent members Strengthened intellectual property position with additional CleanCap® patents in China and Canada Sustainable Growth Enhanced greenhouse gas emissions data collection and expanded Scope 3 emissions reporting Leland, North Carolina facility's solar panels generated over 180,000 kWh, offsetting approximately 20% of facility's energy use San Diego EV charging stations helped save over 19,000 gallons of gasoline Advanced planning for lab plastics recycling program and single-use plastic phase-out The 2024 report was prepared in reference to the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB) and Greenhouse Gas Protocol frameworks and maps selected disclosures to relevant U.N. Sustainable Development Goals (SDGs). About Maravai Maravai LifeSciences is an innovative lifesciences company that provides critical products to enable the development of breakthrough therapeutics, vaccines, cell and gene therapies and diagnostics. Through its TriLink BioTechnologies, Glen Research, Alphazyme and Cygnus Technologies brands, Maravai delivers complex nucleic acid chemistries, differentiated mRNA and enzyme solutions, and gold standard biologics safety tests to a global customer base spanning large pharmaceutical companies, emerging biotechs and leading academic institutions. Forward Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements related to future product offerings, facility capabilities, and sustainability initiatives. Forward-looking statements are neither historical facts nor assurances of future performance and are subject to risks and uncertainties that could cause actual results to differ materially. A detailed discussion of these risks is included in Maravai's most recent Annual Report on Form 10K and subsequent filings with the U.S. Securities and Exchange Commission. Maravai undertakes no obligation to update forward-looking statements except as required by law. CONTACT: Contact Information: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Maravai LifeSciencesReleases 2024 Sustainability Report
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2024 Sustainability Report, available on the Company's Sustainability webpage ( The new report highlights progress during calendar year 2024 across Maravai's four priority areas – Product Innovation, Our People, Governance, and Sustainable Growth – and underscores the Company's commitment to sustainable value creation. 'By embedding sustainability into every facet of our operations—from employee engagement to GMP scaleup — we foster innovation, strengthen our business resilience, and create long-term value for all stakeholders,' said Trey Martin, Chief Executive Officer. 'Our 2024 achievements position Maravai to remain our customers' first choice as they advance their programs in next-generation therapeutics and diagnostics.' Key highlights from the 2024 report include: Product Innovation Launched 49 new products across portfolio brands, including CleanCap® M6 analog now available at GMP quality Completed state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold Established RNA Innovation Center in collaboration with Johns Hopkins University Added to our GMP manufacturing expertise and have now manufactured over 130 GMP batches for mRNA Our People Achieved 95% participation rate in our annual employee engagement survey, receiving over 2,600 comments Expanded WE (We are Empowered) Employee Resource Group to facilitate advocacy, mentorship, and outreach across the organization Implemented new career framework creating transparent progression paths for all employees Continued our Impact Day program throughout 2024, with employees contributing approximately 800 volunteer hours Governance Appointed healthcare industry veteran R. Andrew Eckert as independent Chairman of the Board Adopted formal, publicly available Human Rights Policy 100% of standing Board Committees chaired by independent members Strengthened intellectual property position with additional CleanCap® patents in China and Canada Sustainable Growth Enhanced greenhouse gas emissions data collection and expanded Scope 3 emissions reporting Leland, North Carolina facility's solar panels generated over 180,000 kWh, offsetting approximately 20% of facility's energy use San Diego EV charging stations helped save over 19,000 gallons of gasoline Advanced planning for lab plastics recycling program and single-use plastic phase-out The 2024 report was prepared in reference to the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB) and Greenhouse Gas Protocol frameworks and maps selected disclosures to relevant U.N. Sustainable Development Goals (SDGs). About Maravai Maravai LifeSciences is an innovative lifesciences company that provides critical products to enable the development of breakthrough therapeutics, vaccines, cell and gene therapies and diagnostics. Through its TriLink BioTechnologies, Glen Research, Alphazyme and Cygnus Technologies brands, Maravai delivers complex nucleic acid chemistries, differentiated mRNA and enzyme solutions, and gold standard biologics safety tests to a global customer base spanning large pharmaceutical companies, emerging biotechs and leading academic institutions. Forward Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements related to future product offerings, facility capabilities, and sustainability initiatives. Forward-looking statements are neither historical facts nor assurances of future performance and are subject to risks and uncertainties that could cause actual results to differ materially. A detailed discussion of these risks is included in Maravai's most recent Annual Report on Form 10K and subsequent filings with the U.S. Securities and Exchange Commission. Maravai undertakes no obligation to update forward-looking statements except as required by law. CONTACT: Contact Information: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@ in to access your portfolio
Yahoo
20-05-2025
- Business
- Yahoo
TriLink BioTechnologies® debuts its first mRNA synthesis kit with CleanCap® capping technology; Celebrates launch with kit donations to top academic institutions
New all-in-one IVT kit can deliver up to 2X more mRNA and up to 85% lower dsRNA compared to other kits on the market through streamlined mRNA synthesis with efficient capping, increased yield, reduced dsRNA, and enhanced performance SAN DIEGO, May 20, 2025--(BUSINESS WIRE)--TriLink BioTechnologies® (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI), is fueling the future of mRNA research — starting with a significant donation to top academic labs across the U.S. and Europe. The donation commemorates the launch of TriLink's first mRNA synthesis kit featuring CleanCap® capping technology, an all-in-one kit with its innovative products in one box at a competitive price. Seven academic institutions will receive ten kits each that can yield up to a combined 250mg of capped mRNAs, enabling and encouraging further discovery and development in the field of mRNA-based medicine. Labs in academic institutions, such as those listed below, have gratefully accepted the kits donated by TriLink to drive progress in RNA therapeutics and build a strong future for the field. The Center for RNA Therapeutics at Houston Methodist Research Institute (HMRI) The Center of RNA Technologies and Therapeutics at UC San Diego The University Medical Center Utrecht The University of Oxford Yale School of Medicine The new in vitro transcription (IVT) kit will simplify mRNA synthesis and elevate IVT by leveraging TriLink's high-performing products where users can expect up to 2X more mRNA yield and up to 85% lower dsRNA compared to other kits on the market. The IVT kit components include: CleanCap® AG (3′ OMe) for co-transcriptional capping CleanScribe™ RNA Polymerase for dsRNA reduction Nucleotides including N1-methylpseuouridine for enhanced mRNA performance, and CleanScript® IVT for increased yield. "This launch brings together a powerful suite of novel IVT components that reflect TriLink's years of experience and innovation in mRNA synthesis," shared Justin Barbosa, Vice President & General Manager of TriLink Discovery. "By offering all these components in a single kit, we're simplifying researcher workflow and accelerating discovery. The addition of CleanScript IVT optimization also ensures our customers can generate more high-quality mRNA per reaction — maximizing both efficiency and performance." The kit comes ready to use and is the only commercially available IVT kit featuring CleanCap AG (3′ OMe), which is a modified version of the original CleanCap AG with over 95% capping efficiency to improve protein expression. CleanCap co-transcriptional capping provides advantages over legacy capping methods of ARCA or enzymatic by streamlining mRNA manufacturing with fewer steps and handling, thereby saving researchers time and resources. "This is an important product launch, where we are bringing several technology and process improvements to an integrated IVT kit," said Trey Martin, CEO of Maravai. "Today we are also making a statement about our commitment to the future of mRNA science. By donating the first new kits to top academic institutions across the U.S. and Europe, we are investing in the next generation of mRNA innovators and empowering groundbreaking research that could lead to the therapies of tomorrow. We are honored to help our field continue to evolve and improve through new innovations and process improvements." With more than 25 years of experience in nucleic acid product development and manufacturing, TriLink is a recognized leader in advancing mRNA and oligo-based therapeutic innovation. Its CleanCap AG (3′ OMe) cap analog is used in commercially approved vaccines, of which billion of doses have been administered worldwide with a tremendous safety profile. TriLink's reagents and services are available for research use only (RUO) and for GMP manufacturing, supporting applications from discovery to commercialization in the genomic space. If you are interested in research & development collaboration, visit To learn more about TriLink's products and services, visit About TriLink BioTechnologies TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans. For more information about TriLink, visit About Maravai LifeSciences Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. For more information about Maravai LifeSciences, visit View source version on Contacts Investor Contact:Deb HartMaravai LifeSciences858-988-5917ir@ Media Contact:Liz Robinson of CG LifeTriLink BioTechnologies312-997-2436lrobinson@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
